MENU
+Compare
ALLO
Stock ticker: NASDAQ
AS OF
Dec 18, 04:59 PM (EDT)
Price
$1.91
Change
-$0.17 (-8.21%)
Capitalization
434.02M

ALLO Allogene Therapeutics Forecast, Technical & Fundamental Analysis

a developer of allogeneic chimeric antigen receptor therapy

Industry Biotechnology
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
a Summary for ALLO with price predictions
Dec 17, 2024

ALLO in downward trend: price dove below 50-day moving average on November 13, 2024

ALLO moved below its 50-day moving average on November 13, 2024 date and that indicates a change from an upward trend to a downward trend. In of 35 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 10, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on ALLO as a result. In of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ALLO turned negative on December 05, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .

The 10-day moving average for ALLO crossed bearishly below the 50-day moving average on November 19, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALLO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ALLO entered a downward trend on December 17, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ALLO's RSI Indicator exited the oversold zone, of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ALLO advanced for three days, in of 254 cases, the price rose further within the following month. The odds of a continued upward trend are .

ALLO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ALLO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.931) is normal, around the industry mean (14.664). P/E Ratio (0.000) is within average values for comparable stocks, (87.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.783). ALLO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). ALLO's P/S Ratio (10000.000) is very high in comparison to the industry average of (260.687).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALLO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ALLO is expected to report earnings to rise 1.38% to -32 cents per share on February 26

Allogene Therapeutics ALLO Stock Earnings Reports
Q4'24
Est.
$-0.32
Q3'24
Beat
by $0.01
Q2'24
Est.
$-0.35
Q1'24
Beat
by $0.03
Q4'23
Missed
by $0.06
The last earnings report on November 07 showed earnings per share of -31 cents, beating the estimate of -33 cents. With 1.81M shares outstanding, the current market capitalization sits at 434.02M.
A.I. Advisor
published General Information

General Information

a developer of allogeneic chimeric antigen receptor therapy

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
210 East Grand Avenue
Phone
+1 650 457-2700
Employees
233
Web
https://www.allogene.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GEBCX9.90N/A
N/A
Goldman Sachs ESG Em Mkts Eq C
FDCAX43.16-0.17
-0.39%
Fidelity Capital Appreciation
JHERX20.81-0.11
-0.53%
JHancock Equity Income C
FSCHX14.39-0.08
-0.55%
Fidelity Select Chemicals
EISGX18.52-0.26
-1.38%
Eaton Vance Small-Cap I

ALLO and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ALLO has been loosely correlated with FATE. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ALLO jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALLO
1D Price
Change %
ALLO100%
+0.49%
FATE - ALLO
58%
Loosely correlated
-6.00%
NTLA - ALLO
57%
Loosely correlated
-1.87%
CRBU - ALLO
56%
Loosely correlated
+1.57%
CRSP - ALLO
55%
Loosely correlated
+0.88%
PRME - ALLO
52%
Loosely correlated
-3.00%
More